ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides
ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update
3Q 2026 Gross Margin of 71%, Expanding Approximately 1,450 Basis Points Year- over-Year
Expanding ASCENIV Real-World Health Outcomes Evidence Strengthens Commercial Differentiation
Robust Cash Generation, Operating Leverage and Share Repurchases Support Stockholder Value
- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced its third quarter 2026 financial results and provided a business update.
“Our third quarter results demonstrate ADMA’s ability to translate accelerating ASCENIV demand into substantial earnings growth,” said Adam Grossman, President and Chief Executive Officer of ADMA. “ASCENIV revenue increased 31% year-over- year, driven by expanding physician adoption, new patient starts and growing end-user utilization. Favorable demand trends have continued into the fourth quarter, highlighting the durability of ASCENIV’s growth trajectory and significant remaining market opportunity. We are also encouraged by signs of stabilization in underlying BIVIGAM utilization, despite competitive pressures in the standard immune globulin market. Together with expanding margins and substantial per-share earnings growth, we believe these trends demonstrate the scalability and increasing profitability of our business.”
Mr. Grossman continued, “Our expanding real-world health outcomes evidence strengthens ASCENIV’s clinical value proposition among medically complex primary immunodeficiency patients and supports growing commercial adoption. With our yield-enhanced manufacturing capabilities, robust cash generation and disciplined capital allocation, we believe ADMA is well positioned to deliver sustained, profitable growth and long-term stockholder value creation. We are reiterating our full-year revenue outlook while increasing our minimum expectations for Adjusted Net Income and Adjusted EBITDA and continue to advance SG-001 as a potential additional long-term growth opportunity. We are also encouraged by the constructive FDA feedback recently received on our SG-001 pre- IND meeting package, which we believe represents an important milestone for the program. Notably, we received constructive feedback from the FDA regarding the proposed clinical development strategy, including key elements of the planned clinical study. Based on the FDA’s feedback, we intend to incorporate the recommendations into the final clinical protocol and advance preparations for an IND submission. The FDA also indicated that our proposed assay would be acceptable for product testing, subject to appropriate validation. We believe this feedback supports a potentially efficient development pathway that leverages ADMA’s established manufacturing capabilities and clinical development experience as we advance SG-001 toward clinical trials.” 1 Rei ter ate d F Y20 26 Rev enu e G uid anc e and Inc rea sed Adj ust ed Ear nin gs Out loo k
ADM A’s FY2 026 out loo k r efl ect s c ont inu ed ASC ENI V c omm erc ial mom ent um and con ser vat ive ass ump tio ns for com pet iti ve con dit ion s in the U.S . s tan dar d i mmu ne glo bul in mar ket . F avo rab le ASC ENI V u til iza tio n t ren ds hav e c ont inu ed int o the fou rth qua rte r, whi le und erl yin g B IVI GAM uti liz ati on has sho wn enc our agi ng sig ns of sta bil iza tio n.
ASC ENI V G row th Acc ele rat ed and Mom ent um Ext end ed Int o the Fou rth Qua rte r. ASC ENI V r eve nue in the thi rd qua rte r r eac hed $12 4.7 mil lio n, inc rea sin g 31% yea r-o ver -ye ar and 21% seq uen tia lly , d riv en by exp and ing phy sic ian ado pti on, new pat ien t s tar ts and gro win g e nd- use r u til iza tio n. Fav ora ble pul l-t hro ugh tre nds con tin ued int o the fou rth qua rte r, sup por tin g c onf ide nce in the pro duc t’s gro wth tra jec tor y.
BIV IGA M U til iza tio n S how ed Enc our agi ng Sig ns of Sta bil iza tio n. Thi rd qua rte r B IVI GAM rev enu e was $15 .4 mil lio n, com par ed wit h $ 19. 4 m ill ion in the sec ond qua rte r, ref lec tin g c ont inu ed com pet iti ve pri cin g and cha nne l i nve nto ry pre ssu res in the sta nda rd imm uno glo bul in (IG ) m ark et. Des pit e the seq uen tia l r eve nue dec lin e, und erl yin g e nd- use r u til iza tio n s how ed enc our agi ng sig ns of sta bil iza tio n e nte rin g the fou rth qua rte r. ADM A r ema ins foc use d on dis cip lin ed com mer cia l p art ici pat ion rat her tha n m atc hin g a ggr ess ive com pet ito r r eba tin g and dis cou nti ng.
ASC ENI V R eal -Wo rld Hea lth Out com es Evi den ce Str eng the ned Dif fer ent iat ion . A DMA pla ns to pre sen t an ana lys is of 127 med ica lly com ple x p rim ary imm uno def ici enc y ( “PI ”) pat ien ts tre ate d w ith ASC ENI V, mos t of who m had pre vio usl y r ece ive d o the r i mmu ne glo bul in the rap ies , in mid -No vem ber at the Ame ric an Col leg e of All erg y, Ast hma and Imm uno log y ( ACA AI) ann ual con fer enc e. The ana lys is ide nti fie d s tat ist ica lly sig nif ica nt red uct ion s in inf ect ion -re lat ed hos pit ali zat ion s, out pat ien t h eal thc are uti liz ati on, ora l a nti bio tic use and cor tic ost ero id use fol low ing ASC ENI V i nit iat ion , s upp ort ing its pos iti oni ng amo ng lat er- lin e, ref rac tor y and med ica lly com ple x PI pat ien ts.
The stu dy inc lud ed pat ien ts wit h PI and res pir ato ry com orb idi tie s, sub sta nti al ant imi cro bia l or cor tic ost ero id use , or rec urr ent inf ect ion -re lat ed hea lth car e u til iza tio n.
The ana lys is com par ed out com es dur ing the 12 mon ths bef ore ASC ENI V i nit iat ion wit h the 12 mon ths aft er ini tia tio n. 2 ●
Thi rd- Qua rte r P erf orm anc e D emo nst rat ed Sig nif ica nt Ope rat ing Lev era ge. Tot al rev enu e i ncr eas ed 13% seq uen tia lly to $14 1.1 mil lio n, whi le Adj ust ed EBI TDA gre w 25% qua rte r-o ver -qu art er to $77 .3 mil lio n. Gro ss mar gin rea che d 7 1%, com par ed wit h 69% seq uen tia lly and 56% in the thi rd qua rte r of 202 5, ref lec tin g f avo rab le ASC ENI V mix and ben efi ts fro m y iel d-e nha nce d m anu fac tur ing .
Str ong Cas h G ene rat ion and Dis cip lin ed Cap ita l A llo cat ion Sup por t S toc kho lde r V alu e. ADM A c ont inu ed rep urc has ing sha res of its com mon sto ck whi le inv est ing in com mer cia l g row th, man ufa ctu rin g e ffi cie nci es and SG- 001 dev elo pme nt. Dur ing the thi rd qua rte r, ADM A r epu rch ase d 2.7 mil lio n s har es of com mon sto ck und er its pre vio usl y a uth ori zed sha re rep urc has e p rog ram . Y ear - to- dat e t ota l s toc k r epu rch ase s t hro ugh Sep tem ber 30, 202 6 w ere 16. 5 m ill ion sha res , a mou nti ng to 6.3 % of the Com pan y’s com mon sto ck out sta ndi ng as of Dec emb er 31, 202 5. The Com pan y c ont inu es to act opp ort uni sti cal ly in rep urc has ing sha res and is on tra ck to com ple te its pre vio usl y s tat ed $20 0 m ill ion or mor e 2 026 sha re rep urc has e t arg et.
SG- 001 Dev elo pme nt Pro gre sse d T hro ugh Cap ita l-E ffi cie nt Inn ova tio n. ADM A a dva nce d p rec lin ica l, ass ay dev elo pme nt and man ufa ctu rin g-r ead ine ss act ivi tie s for SG- 001 , its inv est iga tio nal pne umo coc cal hyp eri mmu ne glo bul in can did ate . The Com pan y u sed its pro pri eta ry ADM Aly tic s s cre eni ng and pre dic tiv e a nal yti cs pla tfo rm, inc orp ora tin g c omp uta tio nal mod eli ng and art ifi cia l i nte lli gen ce, to for eca st fin al tit er val ues fro m l imi ted exp eri men tal dat a, wit h the aim of imp rov ing ana lyt ica l e ffi cie ncy and red uci ng lab ora tor y t est ing req uir eme nts in hum ani zed mou se mod els . A DMA exp ect s to lev era ge its exi sti ng man ufa ctu rin g i nfr ast ruc tur e as dev elo pme nt adv anc es. ADM A b eli eve s t hat sho uld SG- 001 rec eiv e FDA app rov al, thi s c oul d r epr ese nt a $ 300 -50 0 m ill ion ann ual rev enu e o ppo rtu nit y for the Com pan y.
The Com pan y r ece ntl y r ece ive d c ons tru cti ve FDA fee dba ck on its SG- 001 pre - IND mee tin g p ack age reg ard ing the pro pos ed cli nic al dev elo pme nt str ate gy, inc lud ing key ele men ts of the pla nne d c lin ica l s tud y. Bas ed on the FDA ’s fee dba ck, the Com pan y i nte nds to inc orp ora te the rec omm end ati ons int o the fin al cli nic al pro toc ol and adv anc e p rep ara tio ns for an IND sub mis sio n. The FDA als o i ndi cat ed tha t A DMA ’s pro pos ed ass ay wou ld be acc ept abl e for pro duc t t est ing , s ubj ect to app rop ria te val ida tio n.
Imm uno com pro mis ed pat ien ts fac e e lev ate d r isk s of sev ere pne umo coc cal dis eas e and may rec eiv e l imi ted pro tec tio n f rom vac cin ati on, und ers cor ing the nee d for tar get ed pre ven tiv e a ppr oac hes . A DMA bel iev es its pre cli nic al fin din gs and rec ent ly rec eiv ed FDA fee dba ck on its pre - IND mee tin g p ack age sup por t c ont inu ed dev elo pme nt of SG- 001 .
Thi rd Qua rte r 2 026 Fin anc ial Res ult s: Total revenue for the quarter ended September 30, 2026 was $141.1 million, compared with $134.2 million for the quarter ended September 30, 2025 and $124.4 million in the second quarter of 2026, representing growth of 5% year-over-year and 13% sequentially. ASCENIV revenue was $124.7 million, increasing 31% year- over-year and 21% sequentially. BIVIGAM revenue was $15.4 million, compared with $23.8 million in the prior-year quarter and $19.4 million in the second quarter of 2026.
Gross profit for the quarter ended September 30, 2026 was $99.9 million, compared with $75.6 million in the prior-year period and $86.3 million in the second quarter of 2026. Gross margin expanded to 71%, compared with 56% in the prior-year quarter and 69% in the second quarter. Margin expansion reflected favorable ASCENIV product mix and the continued benefits of the Company’s yield- enhanced manufacturing process. 3 Research and development expenses for the quarter ended September 30, 2026 were approximately $4.5 million, compared with $1.5 million in the prior-year period and $6.0 million in the second quarter of 2026, reflecting continued SG-001 development investment with lower sequential plasma collection activity.
Selling, general and administrative expenses for the quarter ended September 30, 2026 were approximately $26.6 million, compared with $21.7 million in the prior- year period and $26.7 million in the second quarter of 2026. The year-over-year increase primarily reflected additional personnel and professional fees, as well as legal fees associated with ongoing litigation related matters, while expense levels remained relatively stable sequentially.
GAAP net income for the quarter ended September 30, 2026 was $49.9 million, compared with $36.4 million in the prior-year period and $37.8 million in the second quarter of 2026, representing growth of approximately 37% year-over-year and 32% sequentially.
GAAP basic EPS for the quarter ended September 30, 2026 was $0.22, compared with $0.15 in the prior-year period and $0.17 in the second quarter of 2026 representing growth of approximately 47% year-over-year and 29% sequentially.
Adjusted Net Income for the quarter ended September 30, 2026 was $51.1 million, compared with $38.9 million in the prior-year period and $39.0 million in the second quarter of 2026, increasing approximately 31% year-over-year and sequentially.
Adjusted Basic EPS for the quarter ended September 30, 2026 was $0.23, compared with $0.16 in the prior-year period and $0.17 in the second quarter of 2026, representing growth of approximately 44% year-over-year.
Adjusted EBITDA for the quarter ended September 30, 2026 was $77.3 million, compared with $58.7 million in the prior-year period and $61.8 million in the second quarter of 2026, representing growth of 32% year-over-year and 25% sequentially. Nine Months Ended September 30, 2026 Financial Results: Total revenue for the nine months ended September 30, 2026 was $380.0 million, compared with $371.0 million in the prior-year period, representing growth of 2%. ASCENIV revenue was $325.1 million, increasing 27% year-over-year; BIVIGAM revenue was $50.2 million, compared with $95.0 million in the prior-year period.
Gross profit for the nine months ended September 30, 2026 was $266.9 million, compared with $203.9 million in the prior-year period. Gross margin expanded to 70%, compared with 55% in the prior-year period, reflecting a favorable shift toward ASCENIV and yield-enhancement benefits.
Research and development expenses for the nine months ended September 30, 2026 were approximately $13.1 million, compared with $3.4 million in the prior-year period, primarily reflecting SG-001 development activities.
Selling, general and administrative expenses for the nine months ended September 30, 2026 were approximately $80.0 million, compared with $68.1 million in the prior-year period, primarily reflecting an increase in personnel costs and professional fees, as well as legal fees related to ongoing litigation and related matters.
GAAP net income for the nine months ended September 30, 2026 was $133.0 million, compared with $97.6 million in the prior-year period.
GAAP basic EPS for the nine months ended September 30, 2026 was $0.58, compared with $0.41 in the prior-year period. 4 Adjusted Net Income for the nine months ended September 30, 2026 was $130.7 million, compared with $108.2 million in the prior-year period, representing growth of 21%.
Adjusted Basic EPS for the nine months ended September 30, 2026 was $0.56, compared with $0.45 in the prior-year period, representing growth of 24%.
Adjusted EBITDA for the nine months ended September 30, 2026 was $198.8 million, compared with $157.4 million in the prior-year period, representing growth of 26%.
To seamlessly access the conference call on November 4, 2026 at 4:30 p.m. ET, participants are required to register for the call
to receive the dial-in numbers and unique PIN. It is recommended that you join approximately 10 minutes prior to the event start (although you may dial in at any time during the call). Attendees who will not be asking a question during the call are encouraged to listen in to the live webcast
. An archived replay of the event will be available, located under “Events & Webcasts” in the investor section of the Company’s website at https://ir.admabiologics.com/events-webcasts .
ASCENIV (immune globulin intravenous, human – slra 10% liquid) is a plasma- derived, polyclonal, intravenous immune globulin (IVIG). ASCENIV was approved by the United States Food and Drug Administration (FDA) in April 2019 and is indicated for the treatment of primary humoral immunodeficiency (PI), also known as primary immune deficiency disease (PIDD), in adults and pediatric patients (2 years of age and older). ASCENIV is manufactured using ADMA’s unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends normal source plasma and respiratory syncytial virus (RSV) plasma obtained from donors tested using the Company’s proprietary microneutralization assay. ASCENIV contains naturally occurring polyclonal antibodies, which are proteins that are used by the body’s immune system to neutralize microbes such as bacteria and viruses that safeguard against infection and disease. ASCENIV is protected by numerous issued patents in the United States and internationally and a wide range of patent applications worldwide. Certain data and other information about ASCENIV can be found by visiting www.asceniv.com. Information about ADMA and its products can be found on the Company’s website at www.admabiologics.com.
WARNING: THROMBOSIS, RENAL DYSFUNCTION AND ACUTE RENAL FAILURE Thrombosis may occur with immune globulin intravenous (IGIV) products, including ASCENIV. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with the administration of IGIV products in predisposed patients. Such events require immediate medical intervention, if not recognized or managed appropriately, may result in persistent or significant disability or lead to fatal outcome. For patients at risk of thrombosis, renal dysfunction or renal failure, administer ASCENIV at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.
IgA deficient patients with antibodies to IgA and a history of hypersensitivity.
IgA-deficient patients with antibodies against IgA are at greater risk of developing severe hypersensitivity and anaphylactic reactions. Have medications such as epinephrine available to treat any acute severe hypersensitivity reactions. [4, 5.1]
Thrombotic events have occurred in patients receiving IGIV treatments. Monitor patients with known risk factors for thrombotic events; consider baseline assessment of blood viscosity for patients at risk of hyperviscosity. [5.2, 5.4]
In patients at risk of developing acute renal failure, monitor renal function, including blood urea nitrogen (BUN), serum creatinine, and urine output. [5.3, 5.9]
Hyperproteinemia, increased serum viscosity, and hyponatremia or pseudohyponatremia can occur in patients receiving IGIV treatment. [5.4]
Aseptic meningitis syndrome (AMS) has been reported with IGIV treatments, especially with high doses or rapid infusion. [5.5]
Hemolytic anemia can develop subsequent to IGIV treatment. Monitor patients for hemolysis and hemolytic anemia. [5.6]
Monitor patients for pulmonary adverse reactions (Transfusion-related acute lung injury [TRALI]). If transfusion-related acute lung injury is suspected, test the product and patient for antineutrophil antibodies. [5.7]
Because this product is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. [5.8]
The most common adverse reactions to ASCENIV (≥5% of study subjects) were headache, sinusitis, diarrhea, gastroenteritis viral, nasopharyngitis, upper respiratory tract infection, bronchitis, and nausea.
To report SUSPECTED ADVERSE REACTIONS, contact ADMA Biologics at (800) 458-4244 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6
ADMA Biologics is a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics: ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM® (immune globulin intravenous, human) for the treatment of PI; and NABI-HB ® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Additionally, ADMA is developing SG-001, a pre-clinical, investigative hyperimmune globulin targeting S. pneumoniae . ADMA manufactures its immune globulin products and product candidates at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products and product candidates. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons.
ADMA holds numerous U.S. and foreign patents related to and encompassing various aspects of its products and product candidates. For more information, please visit www.admabiologics.com .
This press release includes certain non-GAAP financial measures that are not prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The Company believes Adjusted EBITDA, Adjusted Net Income, and Adjusted Basic EPS are useful to investors in evaluating the Company’s financial performance. The Company uses Adjusted EBITDA, Adjusted Net Income and Adjusted Basic EPS as key performance measures because it believes that they facilitate operating performance comparisons from period to period that exclude potential differences driven by the impact of variations of non- cash items such as depreciation and amortization, as well as, in the case of Adjusted EBITDA, stock-based compensation or certain non-recurring items, in the case of Adjusted Net Income, certain non-recurring items, and in the case of Adjusted Basic EPS, the impact of the adjustments reflected in Adjusted Net Income on basic weighted average outstanding shares. The Company believes that investors should have access to the same set of tools used by its management and Board of Directors to assess its operating performance. Adjusted EBITDA, Adjusted Net Income and Adjusted Basic EPS should not be considered as measures of financial performance under GAAP, and the items excluded from Adjusted EBITDA, Adjusted Net Income and Adjusted Basic EPS are significant components in understanding and assessing the Company’s financial performance. Accordingly, these key business metrics have limitations as an analytical tool. They should not be considered as an alternative to net income, cash flows from operations, or any other performance measures derived in accordance with GAAP and may be different from similarly titled non-GAAP measures used by other companies. Please refer to the tables below for the reconciliation of GAAP measures to these non-GAAP measures for applicable periods.
The Company has not provided a reconciliation of its forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measure because certain items that are excluded from such non-GAAP financial measures cannot be reasonably predicted or estimated without unreasonable effort. These items may include, but are not limited to, costs associated with potential business development, licensing, collaboration, acquisition, divestiture or other strategic transactions; unusual legal, litigation, regulatory, settlement and related professional fees, expenses and other organizational optimization costs; and other unusual, non-recurring, infrequent or non-cash items that may arise during the applicable period.
The timing, occurrence, and magnitude of these items are inherently uncertain and depend on a variety of factors that are outside of the Company's control or cannot be reasonably predicted at this time. Accordingly, management is unable to estimate these amounts with reasonable certainty or determine the probable significance of such items to the corresponding GAAP financial measure without unreasonable effort. These items could have a material impact on the Company's GAAP results for the applicable reporting period. 7 Cautionary Note Regarding Forward-Looking Statements This press release contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. (“we,” “our” or the “Company”). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain such words as “confident,” “estimate,” “project,” “intend,” “forecast,” “target,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will,” “is likely,” “will likely,” “position us,” “positioned,” “support,” “should,” “could,” “would,” “may,” “potential,” “view,” “opportunity” or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements include, but are not limited to, statements about: the Company’s total revenue, Adjusted Net Income, Adjusted EBITDA, earnings and earnings potential, profitability, scalability, financial guidance in future periods and related assumptions; the Company’s ability to generate stockholder value and related drivers; the current U.S. immune globulin market, including competitive pressures and conditions; ASCENIV revenue growth and potential, value proposition, market opportunity, growth trajectory, appropriate market, adoption, demand and utilization; our ability and plans to complete our 2026 share repurchase target; real-world health outcomes evidence (including, but not limited to, certain patient analyses expected to be presented) and the beneficial impact for ASCENIV’s clinical value and commercial adoption; BIVIGAM potential with signs of stabilization in underlying BIVIGAM utilization; and SG-001, its data, regulatory filings and submissions, revenue potential, growth opportunity and clinical development plans and timeline, the incorporation of FDA feedback into the final clinical protocol, preparations for an IND submission, the potential efficiency of the development pathway, as well as our ability to leverage our existing manufacturing infrastructure in the development of SG-001. Actual events or results may differ materially from those described in this press release due to a number of important factors. Current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements. Forward-looking statements are subject to many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events, to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, the risks and uncertainties described in our filings with the SEC, including our most recent reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.
(1) Adjusted Net Income is a non-GAAP financial measure. The most directly comparable financial measure calculated and presented in accordance with GAAP is Net Income. For a reconciliation of Adjusted Net Income to Net Income, see the reconciliation included in the financial tables. All non-GAAP adjustments are presented pre-tax.
(2) Adjusted Basic EPS is a non-GAAP financial measure. The most directly comparable financial measure calculated and presented in accordance with GAAP is Basic EPS. For a reconciliation of Adjusted Basic EPS to Basic EPS, see the reconciliation included in the financial tables. All non-GAAP adjustments are presented pre-tax. 8 (3) Adjusted EBITDA is a non-GAAP financial measure. The most directly comparable financial measure calculated and presented in accordance with GAAP is Net Income. For a reconciliation of Adjusted EBITDA to Net Income, see the reconciliation included in the financial tables. INVESTOR RELATIONS CONTACT:
(in thousands, except ASSETS share and September December Current per 30, 31, assets: share data) 2026 Unaudited 2025 ────────────────────────────────────────────────────────────────────────────── Cash and cash $ 124,555 $ 87,630 equivale… Accounts receivab… 169,223 158,429 net Inventor… 266,115 206,465 net Prepaid expenses and other 15,969 7,458 current assets Assets held for - 6,530 sale Total current 575,862 466,512 assets Property and 66,761 65,057 equipmen… net Intangib… assets, 581 632 net Goodwill 3,530 3,530 Deferred tax 70,693 73,261 assets, net Right-of… 5,881 6,650 assets Deposits and other 9,177 8,600 assets TOTAL $ 732,485 $ 624,242 ASSETS LIABILIT… AND STOCKHOL… EQUITY Current liabilit… Accounts $ 35,660 $ 22,519 payable Accrued expenses and other 54,217 40,466 current liabilit… Current portion of 4,219 2,813 long-term debt Current portion 1,180 1,096 of lease obligati… Liabilit… held for - 2,647 sale Total current 95,276 69,541 liabilit… Long-term 191,638 69,330 debt Deferred revenue, net of 1,297 1,405 current portion Lease obligati… net of 5,767 6,646 current portion TOTAL $ 293,978 $ 146,922 LIABILIT… COMMITME… AND CONTINGE… STOCKHOL… EQUITY Preferred Stock, $0.0001 par value, 10,000,0… - - shares authoriz… shares issued and outstand… Common Stock - voting, $0.0001 par value, 300,000,… shares authoriz… 30, 2026: 241,251,… 24 24 issued and 222,793,… outstand… December 31, 2025: 239,793,… issued and 237,874,… outstand… Treasury stock, at cost, 18,457,3… and 1,919,070 shares as (213,736 ) (32,090 ) of September 30, 2026and December 31, 2025, respecti… Addition… paid-in 680,838 671,039 capital Accumula… (28,619 ) (161,653 ) deficit TOTAL STOCKHOL… 438,507 477,320 EQUITY TOTAL LIABILIT… AND $ 732,485 $ 624,242 STOCKHOL… EQUITY
(a) Add-backs reflected during the three and nine months ended September 30, 2025 exclude estimated tax effect of $0.6 million and $2.1 million, respectively. Add-backs reflected during the three months and nine months ended September 30, 2026 were tax affected using the respective effective tax rates. 12
(a) Add-backs reflected during the three and nine months ended September 30, 2025 exclude estimated tax effect of $0.6 million and $2.1 million, respectively. Add-backs reflected during the three months and nine months ended September 30, 2026 were tax affected using the respective effective tax rates.
(b) Adjusted basic EPS is measured using basic weighted-average shares outstanding. 13
(1) Due to Nabi-HB historically representing less than 10% of the Company’s revenue within the ADMA BioManufacturing segment, it has been included under intermediates and other products. 14
Nine Months Ended September 30, 2026 2025 (In thousands) CASH FLOWS FROM OPERATING ACTIVITIES: Net income 133,034 97,551 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and 5,409 6,050 amortization Gain on sale of (7,980 ) - plasma centers Loss on disposal of 42 - fixed assets Deferred income tax 2,569 9,848 provision Stock-based 18,667 14,634 compensation Amortization of 589 520 debt discount Loss on extinguishment of - 3,336 debt Amortization of (107 ) (107 ) license revenue Changes in operating assets and liabilities: Accounts receivable (10,794 ) (87,674 ) Inventories (59,650 ) (26,432 ) Prepaid expenses and other current (2,514 ) (978 ) assets Deposits and other 192 (261 ) assets Accounts payable 12,958 4,533 Accrued expenses 13,675 (5,427 ) Other current and non-current (934 ) (836 ) liabilities Net cash provided by operating 105,156 14,757 activities CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of property and (6,801 ) (21,491 ) equipment Acquisition of (119 ) (124 ) intangible assets Proceeds on the sales of assets 5,000 - held for sale Net cash used in investing (1,920 ) (21,615 ) activities CASH FLOWS FROM FINANCING ACTIVITIES: Ares term loan - (32,500 ) payments Ares revolving - (72,500 ) facility payments Ares revolving - 30,000 facility proceeds JPM term loan (1,875 ) (469 ) payments JPM revolving 125,000 75,000 facility proceeds Prepayment penalties on - (1,031 ) repayment of debt Taxes paid on vested restricted (9,769 ) (9,383 ) stock units Debt issuance costs - (2,224 ) Net proceeds from the exercise of 633 2,554 stock options Payment of end of - (1,313 ) term fee Acquisition of (180,300 ) (23,038 ) treasury stock Net cash used in financing (66,311 ) (34,904 ) activities Net increase (decrease) in cash 36,925 (41,762 ) and cash equivalents Cash and cash equivalents - 87,630 103,147 beginning of period Cash and cash equivalents - end $ 124,555 $ 61,385 of period
Full text with the tables
Exhibit 99.1
ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides
Business Update
3Q 2026 Total Revenue of $141.1 Million, Increasing 5% Year-over-Year
3Q 2026 ASCENIV Revenue of $124.7 Million, Increasing 31% Year-over-Year
3Q 2026 GAAP Net Income of $49.9 Million, Increasing 37% Year-over-Year
3Q 2026 Adjusted Net Income (1) of $51.1 Million, Increasing 31% Year-over-Year
3Q 2026 GAAP Basic EPS of $0.22, Increasing 47% Year-over-Year
3Q 2026 Adjusted Basic EPS (2) of $0.23, Increasing 44% Year-over-Year
3Q 2026 Adjusted EBITDA (3) of $77.3 Million, Increasing 32% Year-over-Year
3Q 2026 Gross Margin of 71%, Expanding Approximately 1,450 Basis Points Year-
over-Year
Expanding ASCENIV Real-World Health Outcomes Evidence Strengthens Commercial
Differentiation
Robust Cash Generation, Operating Leverage and Share Repurchases Support
Stockholder Value
Encouraging Regulatory Feedback Received from SG-001 Pre-IND Meeting Package
Reiterates FY2026 Revenue Guidance; Increases Adjusted Earnings Outlook
RAMSEY, N.J. and BOCA RATON, FL, November 4, 2026
- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S.-based,
end-to-end commercial biopharmaceutical company dedicated to manufacturing,
marketing and developing specialty biologics, today announced its third quarter
2026 financial results and provided a business update.
“Our third quarter results demonstrate ADMA’s ability to translate accelerating
ASCENIV demand into substantial earnings growth,” said Adam Grossman, President
and Chief Executive Officer of ADMA. “ASCENIV revenue increased 31% year-over-
year, driven by expanding physician adoption, new patient starts and growing
end-user utilization. Favorable demand trends have continued into the fourth
quarter, highlighting the durability of ASCENIV’s growth trajectory and
significant remaining market opportunity. We are also encouraged by signs of
stabilization in underlying BIVIGAM utilization, despite competitive pressures
in the standard immune globulin market. Together with expanding margins and
substantial per-share earnings growth, we believe these trends demonstrate the
scalability and increasing profitability of our business.”
Mr. Grossman continued, “Our expanding real-world health outcomes evidence
strengthens ASCENIV’s clinical value proposition among medically complex primary
immunodeficiency patients and supports growing commercial adoption. With our
yield-enhanced manufacturing capabilities, robust cash generation and
disciplined capital allocation, we believe ADMA is well positioned to deliver
sustained, profitable growth and long-term stockholder value creation. We are
reiterating our full-year revenue outlook while increasing our minimum
expectations for Adjusted Net Income and Adjusted EBITDA and continue to advance
SG-001 as a potential additional long-term growth opportunity. We are also
encouraged by the constructive FDA feedback recently received on our SG-001 pre-
IND meeting package, which we believe represents an important milestone for the
program. Notably, we received constructive feedback from the FDA regarding the
proposed clinical development strategy, including key elements of the planned
clinical study. Based on the FDA’s feedback, we intend to incorporate the
recommendations into the final clinical protocol and advance preparations for an
IND submission. The FDA also indicated that our proposed assay would be
acceptable for product testing, subject to appropriate validation. We believe
this feedback supports a potentially efficient development pathway that
leverages ADMA’s established manufacturing capabilities and clinical development
experience as we advance SG-001 toward clinical trials.”
1
Rei
ter
ate
d F
Y20
26
Rev
enu
e G
uid
anc
e
and
Inc
rea
sed
Adj
ust
ed
Ear
nin
gs
Out
loo
k
●
FY2
026
tot
al
rev
enu
e e
xpe
cte
d
to
be
at
lea
st
$53
0 m
ill
ion
●
FY2
026
Adj
ust
ed
Net
Inc
ome
exp
ect
ed
to
be
at
lea
st
$18
0 m
ill
ion
●
FY2
026
Adj
ust
ed
EBI
TDA
exp
ect
ed
to
be
at
lea
st
$27
5 m
ill
ion
ADM
A’s
FY2
026
out
loo
k r
efl
ect
s c
ont
inu
ed
ASC
ENI
V c
omm
erc
ial
mom
ent
um
and
con
ser
vat
ive
ass
ump
tio
ns
for
com
pet
iti
ve
con
dit
ion
s
in
the
U.S
. s
tan
dar
d i
mmu
ne
glo
bul
in
mar
ket
. F
avo
rab
le
ASC
ENI
V u
til
iza
tio
n t
ren
ds
hav
e c
ont
inu
ed
int
o
the
fou
rth
qua
rte
r,
whi
le
und
erl
yin
g B
IVI
GAM
uti
liz
ati
on
has
sho
wn
enc
our
agi
ng
sig
ns
of
sta
bil
iza
tio
n.
Thi
rd
Qua
rte
r C
omm
erc
ial
and
Ope
rat
ion
al
Hig
hli
ght
s
●
ASC
ENI
V G
row
th
Acc
ele
rat
ed
and
Mom
ent
um
Ext
end
ed
Int
o
the
Fou
rth
Qua
rte
r.
ASC
ENI
V r
eve
nue
in
the
thi
rd
qua
rte
r r
eac
hed
$12
4.7
mil
lio
n,
inc
rea
sin
g
31%
yea
r-o
ver
-ye
ar
and
21%
seq
uen
tia
lly
, d
riv
en
by
exp
and
ing
phy
sic
ian
ado
pti
on,
new
pat
ien
t s
tar
ts
and
gro
win
g e
nd-
use
r u
til
iza
tio
n.
Fav
ora
ble
pul
l-t
hro
ugh
tre
nds
con
tin
ued
int
o
the
fou
rth
qua
rte
r,
sup
por
tin
g c
onf
ide
nce
in
the
pro
duc
t’s
gro
wth
tra
jec
tor
y.
●
BIV
IGA
M U
til
iza
tio
n S
how
ed
Enc
our
agi
ng
Sig
ns
of
Sta
bil
iza
tio
n.
Thi
rd
qua
rte
r B
IVI
GAM
rev
enu
e
was
$15
.4
mil
lio
n,
com
par
ed
wit
h $
19.
4 m
ill
ion
in
the
sec
ond
qua
rte
r,
ref
lec
tin
g c
ont
inu
ed
com
pet
iti
ve
pri
cin
g
and
cha
nne
l i
nve
nto
ry
pre
ssu
res
in
the
sta
nda
rd
imm
uno
glo
bul
in
(IG
) m
ark
et.
Des
pit
e
the
seq
uen
tia
l r
eve
nue
dec
lin
e,
und
erl
yin
g e
nd-
use
r u
til
iza
tio
n s
how
ed
enc
our
agi
ng
sig
ns
of
sta
bil
iza
tio
n e
nte
rin
g
the
fou
rth
qua
rte
r.
ADM
A r
ema
ins
foc
use
d
on
dis
cip
lin
ed
com
mer
cia
l p
art
ici
pat
ion
rat
her
tha
n m
atc
hin
g a
ggr
ess
ive
com
pet
ito
r r
eba
tin
g
and
dis
cou
nti
ng.
●
ASC
ENI
V R
eal
-Wo
rld
Hea
lth
Out
com
es
Evi
den
ce
Str
eng
the
ned
Dif
fer
ent
iat
ion
. A
DMA
pla
ns
to
pre
sen
t
an
ana
lys
is
of
127
med
ica
lly
com
ple
x p
rim
ary
imm
uno
def
ici
enc
y (
“PI
”)
pat
ien
ts
tre
ate
d w
ith
ASC
ENI
V,
mos
t
of
who
m
had
pre
vio
usl
y r
ece
ive
d o
the
r i
mmu
ne
glo
bul
in
the
rap
ies
,
in
mid
-No
vem
ber
at
the
Ame
ric
an
Col
leg
e
of
All
erg
y,
Ast
hma
and
Imm
uno
log
y (
ACA
AI)
ann
ual
con
fer
enc
e.
The
ana
lys
is
ide
nti
fie
d s
tat
ist
ica
lly
sig
nif
ica
nt
red
uct
ion
s
in
inf
ect
ion
-re
lat
ed
hos
pit
ali
zat
ion
s,
out
pat
ien
t h
eal
thc
are
uti
liz
ati
on,
ora
l a
nti
bio
tic
use
and
cor
tic
ost
ero
id
use
fol
low
ing
ASC
ENI
V i
nit
iat
ion
, s
upp
ort
ing
its
pos
iti
oni
ng
amo
ng
lat
er-
lin
e,
ref
rac
tor
y
and
med
ica
lly
com
ple
x
PI
pat
ien
ts.
o
The
stu
dy
inc
lud
ed
pat
ien
ts
wit
h
PI
and
res
pir
ato
ry
com
orb
idi
tie
s,
sub
sta
nti
al
ant
imi
cro
bia
l
or
cor
tic
ost
ero
id
use
,
or
rec
urr
ent
inf
ect
ion
-re
lat
ed
hea
lth
car
e u
til
iza
tio
n.
o
The
ana
lys
is
com
par
ed
out
com
es
dur
ing
the
12
mon
ths
bef
ore
ASC
ENI
V i
nit
iat
ion
wit
h
the
12
mon
ths
aft
er
ini
tia
tio
n.
2
●
Thi
rd-
Qua
rte
r P
erf
orm
anc
e D
emo
nst
rat
ed
Sig
nif
ica
nt
Ope
rat
ing
Lev
era
ge.
Tot
al
rev
enu
e i
ncr
eas
ed
13%
seq
uen
tia
lly
to
$14
1.1
mil
lio
n,
whi
le
Adj
ust
ed
EBI
TDA
gre
w
25%
qua
rte
r-o
ver
-qu
art
er
to
$77
.3
mil
lio
n.
Gro
ss
mar
gin
rea
che
d 7
1%,
com
par
ed
wit
h
69%
seq
uen
tia
lly
and
56%
in
the
thi
rd
qua
rte
r
of
202
5,
ref
lec
tin
g f
avo
rab
le
ASC
ENI
V
mix
and
ben
efi
ts
fro
m y
iel
d-e
nha
nce
d m
anu
fac
tur
ing
.
●
Str
ong
Cas
h G
ene
rat
ion
and
Dis
cip
lin
ed
Cap
ita
l A
llo
cat
ion
Sup
por
t S
toc
kho
lde
r V
alu
e.
ADM
A c
ont
inu
ed
rep
urc
has
ing
sha
res
of
its
com
mon
sto
ck
whi
le
inv
est
ing
in
com
mer
cia
l g
row
th,
man
ufa
ctu
rin
g e
ffi
cie
nci
es
and
SG-
001
dev
elo
pme
nt.
Dur
ing
the
thi
rd
qua
rte
r,
ADM
A r
epu
rch
ase
d
2.7
mil
lio
n s
har
es
of
com
mon
sto
ck
und
er
its
pre
vio
usl
y a
uth
ori
zed
sha
re
rep
urc
has
e p
rog
ram
. Y
ear
-
to-
dat
e t
ota
l s
toc
k r
epu
rch
ase
s t
hro
ugh
Sep
tem
ber
30,
202
6 w
ere
16.
5 m
ill
ion
sha
res
, a
mou
nti
ng
to
6.3
%
of
the
Com
pan
y’s
com
mon
sto
ck
out
sta
ndi
ng
as
of
Dec
emb
er
31,
202
5.
The
Com
pan
y c
ont
inu
es
to
act
opp
ort
uni
sti
cal
ly
in
rep
urc
has
ing
sha
res
and
is
on
tra
ck
to
com
ple
te
its
pre
vio
usl
y s
tat
ed
$20
0 m
ill
ion
or
mor
e 2
026
sha
re
rep
urc
has
e t
arg
et.
●
SG-
001
Dev
elo
pme
nt
Pro
gre
sse
d T
hro
ugh
Cap
ita
l-E
ffi
cie
nt
Inn
ova
tio
n.
ADM
A a
dva
nce
d p
rec
lin
ica
l,
ass
ay
dev
elo
pme
nt
and
man
ufa
ctu
rin
g-r
ead
ine
ss
act
ivi
tie
s
for
SG-
001
,
its
inv
est
iga
tio
nal
pne
umo
coc
cal
hyp
eri
mmu
ne
glo
bul
in
can
did
ate
.
The
Com
pan
y u
sed
its
pro
pri
eta
ry
ADM
Aly
tic
s s
cre
eni
ng
and
pre
dic
tiv
e a
nal
yti
cs
pla
tfo
rm,
inc
orp
ora
tin
g c
omp
uta
tio
nal
mod
eli
ng
and
art
ifi
cia
l i
nte
lli
gen
ce,
to
for
eca
st
fin
al
tit
er
val
ues
fro
m l
imi
ted
exp
eri
men
tal
dat
a,
wit
h
the
aim
of
imp
rov
ing
ana
lyt
ica
l e
ffi
cie
ncy
and
red
uci
ng
lab
ora
tor
y t
est
ing
req
uir
eme
nts
in
hum
ani
zed
mou
se
mod
els
. A
DMA
exp
ect
s
to
lev
era
ge
its
exi
sti
ng
man
ufa
ctu
rin
g i
nfr
ast
ruc
tur
e
as
dev
elo
pme
nt
adv
anc
es.
ADM
A b
eli
eve
s t
hat
sho
uld
SG-
001
rec
eiv
e
FDA
app
rov
al,
thi
s c
oul
d r
epr
ese
nt
a $
300
-50
0 m
ill
ion
ann
ual
rev
enu
e o
ppo
rtu
nit
y
for
the
Com
pan
y.
o
The
Com
pan
y r
ece
ntl
y r
ece
ive
d c
ons
tru
cti
ve
FDA
fee
dba
ck
on
its
SG-
001
pre
-
IND
mee
tin
g p
ack
age
reg
ard
ing
the
pro
pos
ed
cli
nic
al
dev
elo
pme
nt
str
ate
gy,
inc
lud
ing
key
ele
men
ts
of
the
pla
nne
d c
lin
ica
l s
tud
y.
Bas
ed
on
the
FDA
’s
fee
dba
ck,
the
Com
pan
y i
nte
nds
to
inc
orp
ora
te
the
rec
omm
end
ati
ons
int
o
the
fin
al
cli
nic
al
pro
toc
ol
and
adv
anc
e p
rep
ara
tio
ns
for
an
IND
sub
mis
sio
n.
The
FDA
als
o i
ndi
cat
ed
tha
t A
DMA
’s
pro
pos
ed
ass
ay
wou
ld
be
acc
ept
abl
e
for
pro
duc
t t
est
ing
, s
ubj
ect
to
app
rop
ria
te
val
ida
tio
n.
o
Imm
uno
com
pro
mis
ed
pat
ien
ts
fac
e e
lev
ate
d r
isk
s
of
sev
ere
pne
umo
coc
cal
dis
eas
e
and
may
rec
eiv
e l
imi
ted
pro
tec
tio
n f
rom
vac
cin
ati
on,
und
ers
cor
ing
the
nee
d
for
tar
get
ed
pre
ven
tiv
e a
ppr
oac
hes
. A
DMA
bel
iev
es
its
pre
cli
nic
al
fin
din
gs
and
rec
ent
ly
rec
eiv
ed
FDA
fee
dba
ck
on
its
pre
-
IND
mee
tin
g p
ack
age
sup
por
t c
ont
inu
ed
dev
elo
pme
nt
of
SG-
001
.
Thi
rd
Qua
rte
r 2
026
Fin
anc
ial
Res
ult
s:
Total revenue for the quarter ended September 30, 2026 was $141.1 million,
compared with $134.2 million for the quarter ended September 30, 2025 and $124.4
million in the second quarter of 2026, representing growth of 5% year-over-year
and 13% sequentially. ASCENIV revenue was $124.7 million, increasing 31% year-
over-year and 21% sequentially. BIVIGAM revenue was $15.4 million, compared with
$23.8 million in the prior-year quarter and $19.4 million in the second quarter
of 2026.
Gross profit for the quarter ended September 30, 2026 was $99.9 million,
compared with $75.6 million in the prior-year period and $86.3 million in the
second quarter of 2026. Gross margin expanded to 71%, compared with 56% in the
prior-year quarter and 69% in the second quarter. Margin expansion reflected
favorable ASCENIV product mix and the continued benefits of the Company’s yield-
enhanced manufacturing process.
3
Research and development expenses for the quarter ended September 30, 2026 were
approximately $4.5 million, compared with $1.5 million in the prior-year period
and $6.0 million in the second quarter of 2026, reflecting continued SG-001
development investment with lower sequential plasma collection activity.
Selling, general and administrative expenses for the quarter ended September 30,
2026 were approximately $26.6 million, compared with $21.7 million in the prior-
year period and $26.7 million in the second quarter of 2026. The year-over-year
increase primarily reflected additional personnel and professional fees, as well
as legal fees associated with ongoing litigation related matters, while expense
levels remained relatively stable sequentially.
GAAP net income for the quarter ended September 30, 2026 was $49.9 million,
compared with $36.4 million in the prior-year period and $37.8 million in the
second quarter of 2026, representing growth of approximately 37% year-over-year
and 32% sequentially.
GAAP basic EPS for the quarter ended September 30, 2026 was $0.22, compared with
$0.15 in the prior-year period and $0.17 in the second quarter of 2026
representing growth of approximately 47% year-over-year and 29% sequentially.
Adjusted Net Income for the quarter ended September 30, 2026 was $51.1 million,
compared with $38.9 million in the prior-year period and $39.0 million in the
second quarter of 2026, increasing approximately 31% year-over-year and
sequentially.
Adjusted Basic EPS for the quarter ended September 30, 2026 was $0.23, compared
with $0.16 in the prior-year period and $0.17 in the second quarter of 2026,
representing growth of approximately 44% year-over-year.
Adjusted EBITDA for the quarter ended September 30, 2026 was $77.3 million,
compared with $58.7 million in the prior-year period and $61.8 million in the
second quarter of 2026, representing growth of 32% year-over-year and 25%
sequentially.
Nine Months Ended September 30, 2026 Financial Results:
Total revenue for the nine months ended September 30, 2026 was $380.0 million,
compared with $371.0 million in the prior-year period, representing growth of
2%. ASCENIV revenue was $325.1 million, increasing 27% year-over-year; BIVIGAM
revenue was $50.2 million, compared with $95.0 million in the prior-year period.
Gross profit for the nine months ended September 30, 2026 was $266.9 million,
compared with $203.9 million in the prior-year period. Gross margin expanded to
70%, compared with 55% in the prior-year period, reflecting a favorable shift
toward ASCENIV and yield-enhancement benefits.
Research and development expenses for the nine months ended September 30, 2026
were approximately $13.1 million, compared with $3.4 million in the prior-year
period, primarily reflecting SG-001 development activities.
Selling, general and administrative expenses for the nine months ended September
30, 2026 were approximately $80.0 million, compared with $68.1 million in the
prior-year period, primarily reflecting an increase in personnel costs and
professional fees, as well as legal fees related to ongoing litigation and
related matters.
GAAP net income for the nine months ended September 30, 2026 was $133.0 million,
compared with $97.6 million in the prior-year period.
GAAP basic EPS for the nine months ended September 30, 2026 was $0.58, compared
with $0.41 in the prior-year period.
4
Adjusted Net Income for the nine months ended September 30, 2026 was $130.7
million, compared with $108.2 million in the prior-year period, representing
growth of 21%.
Adjusted Basic EPS for the nine months ended September 30, 2026 was $0.56,
compared with $0.45 in the prior-year period, representing growth of 24%.
Adjusted EBITDA for the nine months ended September 30, 2026 was $198.8 million,
compared with $157.4 million in the prior-year period, representing growth of
26%.
Conference Call Information
To seamlessly access the conference call on November 4, 2026 at 4:30 p.m. ET,
participants are required to register for the call
here
to receive the dial-in numbers and unique PIN. It is recommended that you join
approximately 10 minutes prior to the event start (although you may dial in at
any time during the call). Attendees who will not be asking a question during
the call are encouraged to listen in to the live webcast
here
. An archived replay of the event will be available, located under “Events &
Webcasts” in the investor section of the Company’s website at
https://ir.admabiologics.com/events-webcasts .
About ASCENIV™
ASCENIV (immune globulin intravenous, human – slra 10% liquid) is a plasma-
derived, polyclonal, intravenous immune globulin (IVIG). ASCENIV was approved by
the United States Food and Drug Administration (FDA) in April 2019 and is
indicated for the treatment of primary humoral immunodeficiency (PI), also known
as primary immune deficiency disease (PIDD), in adults and pediatric patients (2
years of age and older). ASCENIV is manufactured using ADMA’s unique, patented
plasma donor screening methodology and tailored plasma pooling design, which
blends normal source plasma and respiratory syncytial virus (RSV) plasma
obtained from donors tested using the Company’s proprietary microneutralization
assay. ASCENIV contains naturally occurring polyclonal antibodies, which are
proteins that are used by the body’s immune system to neutralize microbes such
as bacteria and viruses that safeguard against infection and disease. ASCENIV is
protected by numerous issued patents in the United States and internationally
and a wide range of patent applications worldwide. Certain data and other
information about ASCENIV can be found by visiting www.asceniv.com. Information
about ADMA and its products can be found on the Company’s website at
www.admabiologics.com.
Additional Important Safety Information About ASCENIV™
WARNING:
THROMBOSIS, RENAL DYSFUNCTION AND ACUTE RENAL
FAILURE
Thrombosis may occur with immune globulin intravenous (IGIV) products,
including ASCENIV. Risk factors may include: advanced age, prolonged
immobilization, hypercoagulable conditions, history of venous or arterial
thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity,
and cardiovascular risk factors.
Renal dysfunction, acute renal failure, osmotic nephrosis, and death may
occur with the administration of IGIV products in predisposed patients. Such
events require immediate medical intervention, if not recognized or managed
appropriately, may result in persistent or significant disability or lead to
fatal outcome.
For patients at risk of thrombosis, renal dysfunction or renal failure,
administer ASCENIV at the minimum dose and infusion rate practicable. Ensure
adequate hydration in patients before administration. Monitor for signs and
symptoms of thrombosis and assess blood viscosity in patients at risk for
hyperviscosity.
5
ASCENIV™ Contraindications:
History of anaphylactic or severe systemic reactions to human immunoglobulin.
IgA deficient patients with antibodies to IgA and a history of hypersensitivity.
ASCENIV™ Warnings and Precautions:
IgA-deficient patients with antibodies against IgA are at greater risk of
developing severe hypersensitivity and anaphylactic reactions. Have medications
such as epinephrine available to treat any acute severe hypersensitivity
reactions. [4, 5.1]
Thrombotic events have occurred in patients receiving IGIV treatments. Monitor
patients with known risk factors for thrombotic events; consider baseline
assessment of blood viscosity for patients at risk of hyperviscosity. [5.2, 5.4]
In patients at risk of developing acute renal failure, monitor renal function,
including blood urea nitrogen (BUN), serum creatinine, and urine output. [5.3,
5.9]
Hyperproteinemia, increased serum viscosity, and hyponatremia or
pseudohyponatremia can occur in patients receiving IGIV treatment. [5.4]
Aseptic meningitis syndrome (AMS) has been reported with IGIV treatments,
especially with high doses or rapid infusion. [5.5]
Hemolytic anemia can develop subsequent to IGIV treatment. Monitor patients for
hemolysis and hemolytic anemia. [5.6]
Monitor patients for pulmonary adverse reactions (Transfusion-related acute lung
injury [TRALI]). If transfusion-related acute lung injury is suspected, test the
product and patient for antineutrophil antibodies. [5.7]
Because this product is made from human blood, it may carry a risk of
transmitting infectious agents, e.g., viruses, and theoretically, the
Creutzfeldt-Jakob disease (CJD) agent. [5.8]
ASCENIV™ Adverse Reactions:
The most common adverse reactions to ASCENIV (≥5% of study subjects) were
headache, sinusitis, diarrhea, gastroenteritis viral, nasopharyngitis, upper
respiratory tract infection, bronchitis, and nausea.
To report SUSPECTED ADVERSE REACTIONS, contact ADMA Biologics at (800) 458-4244
or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
6
About ADMA Biologics, Inc. (ADMA)
ADMA Biologics is a U.S.-based, end-to-end commercial biopharmaceutical company
dedicated to manufacturing, marketing and developing specialty biologics for the
treatment of immunodeficient patients at risk for infection and others at risk
for certain infectious diseases. ADMA currently manufactures and markets three
United States Food and Drug Administration (FDA)-approved plasma-derived
biologics: ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for
the treatment of primary humoral immunodeficiency (PI); BIVIGAM® (immune
globulin intravenous, human) for the treatment of PI; and NABI-HB ® (hepatitis B
immune globulin, human) to provide enhanced immunity against the hepatitis B
virus. Additionally, ADMA is developing SG-001, a pre-clinical, investigative
hyperimmune globulin targeting S. pneumoniae . ADMA manufactures its immune
globulin products and product candidates at its FDA-licensed plasma
fractionation and purification facility located in Boca Raton, Florida. Through
its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source
plasma collector in the U.S., which provides a portion of its blood plasma for
the manufacture of its products and product candidates. ADMA’s mission is to
manufacture, market and develop specialty plasma-derived, human immune globulins
targeted to niche patient populations for the treatment and prevention of
certain infectious diseases and management of immune compromised patient
populations who suffer from an underlying immune deficiency, or who may be
immune compromised for other medical reasons.
ADMA holds numerous U.S. and foreign patents related to and encompassing various
aspects of its products and product candidates. For more information, please
visit www.admabiologics.com .
Use of Non-GAAP Financial Measures
This press release includes certain non-GAAP financial measures that are not
prepared in accordance with accounting principles generally accepted in the
United States (“GAAP”). The Company believes Adjusted EBITDA, Adjusted Net
Income, and Adjusted Basic EPS are useful to investors in evaluating the
Company’s financial performance. The Company uses Adjusted EBITDA, Adjusted Net
Income and Adjusted Basic EPS as key performance measures because it believes
that they facilitate operating performance comparisons from period to period
that exclude potential differences driven by the impact of variations of non-
cash items such as depreciation and amortization, as well as, in the case of
Adjusted EBITDA, stock-based compensation or certain non-recurring items, in the
case of Adjusted Net Income, certain non-recurring items, and in the case of
Adjusted Basic EPS, the impact of the adjustments reflected in Adjusted Net
Income on basic weighted average outstanding shares. The Company believes that
investors should have access to the same set of tools used by its management and
Board of Directors to assess its operating performance. Adjusted EBITDA,
Adjusted Net Income and Adjusted Basic EPS should not be considered as measures
of financial performance under GAAP, and the items excluded from Adjusted
EBITDA, Adjusted Net Income and Adjusted Basic EPS are significant components in
understanding and assessing the Company’s financial performance. Accordingly,
these key business metrics have limitations as an analytical tool. They should
not be considered as an alternative to net income, cash flows from operations,
or any other performance measures derived in accordance with GAAP and may be
different from similarly titled non-GAAP measures used by other companies.
Please refer to the tables below for the reconciliation of GAAP measures to
these non-GAAP measures for applicable periods.
The Company has not provided a reconciliation of its forward-looking non-GAAP
financial measures to the most directly comparable GAAP financial measure
because certain items that are excluded from such non-GAAP financial measures
cannot be reasonably predicted or estimated without unreasonable effort. These
items may include, but are not limited to, costs associated with potential
business development, licensing, collaboration, acquisition, divestiture or
other strategic transactions; unusual legal, litigation, regulatory, settlement
and related professional fees, expenses and other organizational optimization
costs; and other unusual, non-recurring, infrequent or non-cash items that may
arise during the applicable period.
The timing, occurrence, and magnitude of these items are inherently uncertain
and depend on a variety of factors that are outside of the Company's control or
cannot be reasonably predicted at this time. Accordingly, management is unable
to estimate these amounts with reasonable certainty or determine the probable
significance of such items to the corresponding GAAP financial measure without
unreasonable effort. These items could have a material impact on the Company's
GAAP results for the applicable reporting period.
7
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995, about
ADMA Biologics, Inc. (“we,” “our” or the “Company”). Forward-looking statements
include, without limitation, any statement that may predict, forecast, indicate,
or imply future results, performance or achievements, and may contain such words
as “confident,” “estimate,” “project,” “intend,” “forecast,” “target,”
“anticipate,” “plan,” “planning,” “expect,” “believe,” “will,” “is likely,”
“will likely,” “position us,” “positioned,” “support,” “should,” “could,”
“would,” “may,” “potential,” “view,” “opportunity” or, in each case, their
negative, or words or expressions of similar meaning. These forward-looking
statements include, but are not limited to, statements about: the Company’s
total revenue, Adjusted Net Income, Adjusted EBITDA, earnings and earnings
potential, profitability, scalability, financial guidance in future periods and
related assumptions; the Company’s ability to generate stockholder value and
related drivers; the current U.S. immune globulin market, including competitive
pressures and conditions; ASCENIV revenue growth and potential, value
proposition, market opportunity, growth trajectory, appropriate market,
adoption, demand and utilization; our ability and plans to complete our 2026
share repurchase target; real-world health outcomes evidence (including, but not
limited to, certain patient analyses expected to be presented) and the
beneficial impact for ASCENIV’s clinical value and commercial adoption; BIVIGAM
potential with signs of stabilization in underlying BIVIGAM utilization; and
SG-001, its data, regulatory filings and submissions, revenue potential, growth
opportunity and clinical development plans and timeline, the incorporation of
FDA feedback into the final clinical protocol, preparations for an IND
submission, the potential efficiency of the development pathway, as well as our
ability to leverage our existing manufacturing infrastructure in the development
of SG-001. Actual events or results may differ materially from those described
in this press release due to a number of important factors. Current and
prospective security holders are cautioned that there also can be no assurance
that the forward-looking statements included in this press release will prove to
be accurate. Except to the extent required by applicable laws or rules, ADMA
does not undertake any obligation to update any forward-looking statements or to
announce revisions to any of the forward-looking statements. Forward-looking
statements are subject to many risks, uncertainties and other factors that could
cause our actual results, and the timing of certain events, to differ materially
from any future results expressed or implied by the forward-looking statements,
including, but not limited to, the risks and uncertainties described in our
filings with the SEC, including our most recent reports on Form 10-K, 10-Q and
8-K, and any amendments thereto.
(1) Adjusted Net Income is a non-GAAP financial measure. The most directly
comparable financial measure calculated and presented in accordance with GAAP is
Net Income. For a reconciliation of Adjusted Net Income to Net Income, see the
reconciliation included in the financial tables. All non-GAAP adjustments are
presented pre-tax.
(2) Adjusted Basic EPS is a non-GAAP financial measure. The most directly
comparable financial measure calculated and presented in accordance with GAAP is
Basic EPS. For a reconciliation of Adjusted Basic EPS to Basic EPS, see the
reconciliation included in the financial tables. All non-GAAP adjustments are
presented pre-tax.
8
(3) Adjusted EBITDA is a non-GAAP financial measure. The most directly
comparable financial measure calculated and presented in accordance with GAAP is
Net Income. For a reconciliation of Adjusted EBITDA to Net Income, see the
reconciliation included in the financial tables.
INVESTOR RELATIONS CONTACT:
Argot Partners | 212-600-1902 | [email protected]
MEDIA CONTACT:
Longacre Square Partners | [email protected]
9
ADMA BIOLOGICS, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS
(in
thousands,
except
ASSETS share and September December
Current per 30, 31,
assets: share data) 2026 Unaudited 2025
──────────────────────────────────────────────────────────────────────────────
Cash and
cash $ 124,555 $ 87,630
equivale…
Accounts
receivab… 169,223 158,429
net
Inventor… 266,115 206,465
net
Prepaid
expenses
and other 15,969 7,458
current
assets
Assets
held for - 6,530
sale
Total
current 575,862 466,512
assets
Property
and 66,761 65,057
equipmen…
net
Intangib…
assets, 581 632
net
Goodwill 3,530 3,530
Deferred
tax 70,693 73,261
assets,
net
Right-of… 5,881 6,650
assets
Deposits
and other 9,177 8,600
assets
TOTAL $ 732,485 $ 624,242
ASSETS
LIABILIT…
AND
STOCKHOL…
EQUITY
Current
liabilit…
Accounts $ 35,660 $ 22,519
payable
Accrued
expenses
and other 54,217 40,466
current
liabilit…
Current
portion
of 4,219 2,813
long-term
debt
Current
portion 1,180 1,096
of lease
obligati…
Liabilit…
held for - 2,647
sale
Total
current 95,276 69,541
liabilit…
Long-term 191,638 69,330
debt
Deferred
revenue,
net of 1,297 1,405
current
portion
Lease
obligati…
net of 5,767 6,646
current
portion
TOTAL $ 293,978 $ 146,922
LIABILIT…
COMMITME…
AND
CONTINGE…
STOCKHOL…
EQUITY
Preferred
Stock,
$0.0001
par
value,
10,000,0… - -
shares
authoriz…
shares
issued
and
outstand…
Common
Stock -
voting,
$0.0001
par
value,
300,000,…
shares
authoriz…
30, 2026:
241,251,… 24 24
issued
and
222,793,…
outstand…
December
31, 2025:
239,793,…
issued
and
237,874,…
outstand…
Treasury
stock, at
cost,
18,457,3…
and
1,919,070
shares as (213,736 ) (32,090 )
of
September
30,
2026and
December
31, 2025,
respecti…
Addition…
paid-in 680,838 671,039
capital
Accumula… (28,619 ) (161,653 )
deficit
TOTAL
STOCKHOL… 438,507 477,320
EQUITY
TOTAL
LIABILIT…
AND $ 732,485 $ 624,242
STOCKHOL…
EQUITY
10
ADMA BIOLOGICS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS
NON-GAAP RECONCILIATION
Three
Mont…
Ended
Sept…
30,
2026
(in
thou…
exce…
share Nine
and Mon…
per End…
share Sep…
data) 30,
Unau… 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
REV… $ 141,… $ 134,… $ 379,… $ 371…
Cost
of 41,1… 58,5… 113,… 167…
pro…
rev…
Gro… 99,9… 75,6… 266,… 203…
pro…
OPE…
EXP…
Res…
and 4,490 1,528 13,1… 3,3…
dev…
Pla…
cen… 1,055 1,272 3,143 3,7…
ope…
exp…
Amo…
of 60 38 170 93
int…
ass…
Gain
on
sale - - (7,9… ) -
of
pla…
cen…
Sel…
gen… 26,5… 21,7… 80,0… 68,…
and
adm…
Tot…
ope… 32,1… 24,6… 88,4… 75,…
exp…
INC…
FROM 67,7… 51,0… 178,… 128…
OPE…
OTH…
INC…
(EX…
Int…
and 1,298 376 3,629 1,3…
oth…
inc…
Int… (3,4… ) (1,6… ) (8,9… ) (5,… )
exp…
Loss
on
ext… - (2,1… ) - (3,… )
of
debt
Oth… (19 ) (21 ) (180 ) (195 )
exp…
Oth…
inc… (2,1… ) (3,4… ) (5,5… ) (7,… )
(ex…
net
INC…
BEF… 65,6… 47,5… 172,… 121…
INC…
TAX…
Pro…
for 15,7… 11,0… 39,9… 23,…
inc…
tax…
NET $ 49,8… $ 36,4… $ 133,… $ 97,…
INC…
BAS…
EAR…
PER $ 0.22 $ 0.15 $ 0.58 $ 0.41
COM…
SHA…
DIL…
EAR…
PER $ 0.22 $ 0.15 $ 0.57 $ 0.40
COM…
SHA…
WEI…
AVE…
COM…
SHA…
OUT…
Bas… 223,… 238,… 229,… 238…
Dil… 225,… 244,… 232,… 245…
11
RECONCILIATION OF GAAP NET INCOME TO ADJUSTED EBITDA (3)
Three
Months
Ended
Septe… Nine
30, Months
2026 Ended
(in Septe…
thous… 30,
Unaud… 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net $ 49,884 $ 36,428 $ 133,0… $ 97,551
inco…
Depr… 1,729 1,987 5,239 5,957
Amor… 60 38 170 93
Inco… 15,720 11,087 39,935 23,510
taxes
Inte…
expe… 2,134 1,675 5,303 5,484
net
EBIT… 69,527 51,215 183,6… 132,5…
Stoc… 6,203 5,047 18,666 14,634
comp…
Volu…
With…
and - - - 4,001
prod…
repl…
Yield 181 301 1,022 1,696
enha…
Gain
on
sale - - (7,980 ) -
of
plas…
cent…
Loss
on
exti… - 2,177 - 3,336
of
debt
Non-…
prof… 1,368 - 3,388 1,182
fees
Adju… $ 77,279 $ 58,740 $ 198,7… $ 157,4…
EBIT…
NON-GAAP RECONCILIATION
RECONCILIATION OF GAAP NET INCOME TO ADJUSTED NET INCOME (1)
Three Nine
Mont… Mont…
Ended Ended
(in Sept… Sept…
thou… 30, 30,
Unau… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net $ 49,8… $ 36,428 $ 133,0… $ 97,5…
inc…
Sto…
com… - - 609 474
mod…
Cus…
cre…
rel…
to - - - 4,001
the
Vol…
Wit…
Loss
on
ext… - 2,177 - 3,336
of
debt
Yie… 138 301 788 1,696
Enh…
Gain
on
sale - - (6,332 ) -
of
pla…
cen…
Non…
pro… 1,040 - 2,599 1,182
fees
Adj…
net $ 51,0… $ 38,906 $ 130,6… $ 108,…
inc…
(a) Add-backs reflected during the three and nine months ended September 30,
2025 exclude estimated tax effect of $0.6 million and $2.1 million,
respectively. Add-backs reflected during the three months and nine months ended
September 30, 2026 were tax affected using the respective effective tax rates.
12
NON-GAAP RECONCILIATION
RECONCILIATION OF
BASIC EARNINGS PER SHARE TO
ADJUSTED EARNINGS PER SHARE (2)
Three
Months
Ended
Septe… Nine
30, Months
2026 Ended
(in Septe…
thous… 30,
Unaud… 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net $ 49,884 $ 36,428 $ 133,0… $ 97,551
inco…
Stoc…
comp… - - 609 474
modi…
Cust…
cred…
rela…
to - - - 4,001
the
Volu…
With…
Loss
on
exti… - 2,177 - 3,336
of
debt
Yield 138 301 788 1,696
Enha…
Gain
on
sale - - (6,332 ) -
of
plas…
cent…
Non-…
prof… 1,040 - 2,599 1,182
fees
Adju…
net $ 51,062 $ 38,906 $ 130,6… $ 108,2…
inco…
Basic
earn…
per $ 0.22 $ 0.15 $ 0.58 $ 0.41
comm…
share
Stoc…
comp… - - - -
modi…
Cust…
cred…
rela…
to - - - 0.02
the
Volu…
With…
Loss
on
exti… - 0.01 - 0.01
of
debt
Yield - - - 0.01
Enha…
Gain
on
sale - - (0.03 ) -
of
plas…
cent…
Non-…
prof… 0.01 - 0.01 -
fees
Adju…
basic $ 0.23 $ 0.16 $ 0.56 $ 0.45
EPS(…
(a) Add-backs reflected during the three and nine months ended September 30,
2025 exclude estimated tax effect of $0.6 million and $2.1 million,
respectively. Add-backs reflected during the three months and nine months ended
September 30, 2026 were tax affected using the respective effective tax rates.
(b) Adjusted basic EPS is measured using basic weighted-average shares
outstanding.
13
PRODUCT-LEVEL TOTAL REVENUE
… …
… …
… …
… … … …
… … … … … …
… … … … % … … … %
──────────────────────────────────────────────────────────────────────────────
$ … $ … $ … … % $ … $ … $ … …
… … … ) … … … … … ) …
… … … ) … … … … … ) …
… … … … % … … … …
… - … … % … … … …
… … - … % … … - …
$ … $ … $ … … % $ … $ … $ … …
(1) Due to Nabi-HB historically representing less than 10% of the Company’s
revenue within the ADMA BioManufacturing segment, it has been included under
intermediates and other products.
14
ADMA BIOLOGICS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENT OF CASH FLOWS
Nine Months Ended
September 30,
2026 2025
(In thousands)
CASH FLOWS FROM
OPERATING
ACTIVITIES:
Net income 133,034 97,551
Adjustments to
reconcile net
income to
net
cash provided by
operating
activities:
Depreciation and 5,409 6,050
amortization
Gain on sale of (7,980 ) -
plasma centers
Loss on disposal of 42 -
fixed assets
Deferred income tax 2,569 9,848
provision
Stock-based 18,667 14,634
compensation
Amortization of 589 520
debt discount
Loss on
extinguishment of - 3,336
debt
Amortization of (107 ) (107 )
license revenue
Changes in
operating assets
and
liabilities:
Accounts receivable (10,794 ) (87,674 )
Inventories (59,650 ) (26,432 )
Prepaid expenses
and other current (2,514 ) (978 )
assets
Deposits and other 192 (261 )
assets
Accounts payable 12,958 4,533
Accrued expenses 13,675 (5,427 )
Other current and
non-current (934 ) (836 )
liabilities
Net cash provided
by operating 105,156 14,757
activities
CASH FLOWS FROM
INVESTING
ACTIVITIES:
Purchase of
property and (6,801 ) (21,491 )
equipment
Acquisition of (119 ) (124 )
intangible assets
Proceeds on the
sales of assets 5,000 -
held for
sale
Net cash used in
investing (1,920 ) (21,615 )
activities
CASH FLOWS FROM
FINANCING
ACTIVITIES:
Ares term loan - (32,500 )
payments
Ares revolving - (72,500 )
facility payments
Ares revolving - 30,000
facility proceeds
JPM term loan (1,875 ) (469 )
payments
JPM revolving 125,000 75,000
facility proceeds
Prepayment
penalties on - (1,031 )
repayment of
debt
Taxes paid on
vested restricted (9,769 ) (9,383 )
stock
units
Debt issuance costs - (2,224 )
Net proceeds from
the exercise of 633 2,554
stock
options
Payment of end of - (1,313 )
term fee
Acquisition of (180,300 ) (23,038 )
treasury stock
Net cash used in
financing (66,311 ) (34,904 )
activities
Net increase
(decrease) in cash 36,925 (41,762 )
and cash
equivalents
Cash and cash
equivalents - 87,630 103,147
beginning of
period
Cash and cash
equivalents - end $ 124,555 $ 61,385
of
period